Clinical trials: Eosinophilic Asthma Patients
Asthma
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions
The main aim of this study is to investigate the change in asthma control after 6 months of therapy in patients treated with benralizumab biologic therapy for severe eosinophilic asthma under real-life conditions in a pulmonary…
- Trial name
- imPROve (NCT04184284)
- Where
- 50 sites in Germany
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who at the discretion of…
- Trial name
- ORBE (NCT04126499)
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Asthma
Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma
- Trial name
- MEMORY (NCT02594332)
- Testing
- Mepolizumab
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Johannes Gutenberg University Mainz
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma Brittle
Exploring Asthma Exacerbations in Mepolizumab Treated Patients
This is a multicentre, observational study focusing on exacerbation events in patients with severe eosinophilic asthma on Mepolizumab.
- Trial name
- NCT03324230
- Where
- 4 sites in United Kingdom
- Volunteers
- 146 people
- Sponsor
- Queen's University, Belfast
Steroid and/or Prednisone Dependent Asthma, Eosinophilic Bronchitis
Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
The purpose of this study is to investigate whether addition of Omalizumab enables a reduction in the dose of prednisone in patients with asthma and eosinophilic bronchitis.
- Trial name
- NCT02049294
- Testing
- Omalizumab (Xolair)
- Where
- 5 sites in Canada
- Volunteers
- 11 people
- Sponsor
- McMaster University
Eosinophilic Asthma Patients
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
The purpose of this study is to evaluation the long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
- Trial name
- NCT06441812
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma
A Study to Test if TEV-53275 is Effective in Relieving Asthma
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo.
- Trial name
- NCT04847674
- Testing
- TEV-53275 Dose A, TEV-53275 Dose B
- Where
- 82 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple Indications
Glucocorticoids are important in the treatment of many inflammatory, allergic, immunologic, and malignant disorders. However, the adverse effects of systemic corticosteroids are one of the most common causes of iatrogenic…
- Trial name
- NCT06488703
- Where
- Germany
- Volunteers
- 107,032 people
- Sponsor
- GlaxoSmithKline
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma, Eosinophilic Asthma
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed…
- Trial name
- NCT04674137
- Testing
- XC8 100 mg
- Where
- 18 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Chemlmmune Therapeutics LLC
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Asthma
Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma
Background: Asthma is a common chronic condition characterized by respiratory symptoms and hyperresponsive airways. According to treatment guidelines, patients with persistent asthma require daily treatment with inhaled…
- Trial name
- NCT03141424
- Testing
- Tapering of inhaled corticosteroid (ICS) treatment
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Hvidovre University Hospital
Asthma
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
Primary Objective: To investigate the effects of Dupilumab (SAR231893/REGN668) administered subcutaneously (SC) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants…
- Trial name
- NCT01312961
- Testing
- Dupilumab, Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy
- Where
- 50 sites in United States
- Volunteers
- 104 people
- Sponsor
- Sanofi
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller…
- Trial name
- PONENTE (NCT03557307)
- Testing
- Benralizumab
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Asthmatic Bronchitis
Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis
This study aims to identify and validate the gene expression differentials of peripheral blood mononuclear cells and differential inflammation profiles and other aspects in classic asthma, cough-variant asthma and eosinophilic…
- Trial name
- NCT02555345
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- State Key Laboratory of Respiratory Disease